The major challenge for the CRC for Cancer Therapeutics (CTx) is to address the leading single cause of death in Australia – cancer. CTx discovers, protects and develops small molecules into pre-clinical drug candidates with high commercial potential. These candidates are chosen for their ability to better target cancer cells rather than normal healthy cells, to improve clinical outcomes and produce large healthcare system efficiencies.

 Please note: This authority is not technically subject to FOI, but you can still make requests to it